Actos Litigation 2024: Eligibility, Status, and Settlement Updates

If you or a loved one took the type 2 diabetes medication Actos (generic name: pioglitazone) and later received a bladder cancer diagnosis, you may be eligible for compensation through ongoing Actos litigation. First approved by the FDA in 1999, Actos was marketed by Takeda Pharmaceuticals as a safe, effective treatment to lower blood sugar for adults with type 2 diabetes. But by 2011, the FDA issued a formal safety warning linking long-term Actos use (12+ months) to a 40% increased risk of bladder cancer. Thousands of plaintiffs have filed claims against Takeda alleging the company hid known safety risks, falsified clinical trial data, and failed to warn patients and providers of the cancer risk. This guide breaks down everything you need to know about Actos litigation, from eligibility requirements to current case status and settlement details.

Table of Contents#

  1. What Is Actos, and Why Are Lawsuits Filed?
  2. Actos Litigation Eligibility Criteria
  3. Current Status of Actos Litigation
  4. Actos Settlement Details: Payouts, Covered Costs, and Tax Rules
  5. Next Steps If You Qualify for an Actos Claim
  6. Frequently Asked Questions
  7. References

What Is Actos, and Why Are Lawsuits Filed?#

Actos belongs to a class of diabetes drugs called thiazolidinediones, which work by reducing insulin resistance in the body. At its peak, over 10 million Americans had prescriptions for Actos. Lawsuits against Takeda and generic pioglitazone manufacturers are based on three core allegations:

  1. Failure to warn: Internal Takeda documents show the company was aware of bladder cancer risks but did not disclose this information to regulators, providers, or patients for years before the FDA's 2011 safety warning.
  2. Destroyed evidence: Court proceedings revealed that Takeda systematically destroyed documents and emails related to Actos’ safety risks. In 2014, a jury ordered Takeda to pay $155,000 for destroying evidence relevant to the litigation.
  3. Off-label promotion: Takeda illegally marketed Actos for use in patients with prediabetes and type 1 diabetes, uses not approved by the FDA, exposing more people to unnecessary cancer risk. Plaintiffs seek compensation for damages associated with Actos-related bladder cancer, including medical bills, lost income, and pain and suffering. Wrongful death claims are also filed by families of patients who died from Actos-linked bladder cancer.

Actos Litigation Eligibility Criteria#

Not everyone who took Actos qualifies to file a claim. To be eligible, you must meet all of the following standard criteria: ✅ You took brand name Actos or generic pioglitazone for at least 12 consecutive months before your bladder cancer diagnosis. Higher priority is given to people who took the drug for 2+ years, as the cancer risk rises significantly with extended use. ✅ You received a formal diagnosis of urothelial (bladder) cancer after 2005. You are not eligible if you had a bladder cancer diagnosis before taking Actos. ✅ You have not previously filed an Actos claim or accepted a settlement from Takeda or a generic manufacturer. ✅ Your claim is filed before your state’s statute of limitations expires. Most states set a 2–3 year deadline from the date of your bladder cancer diagnosis to file a personal injury claim, and 1–2 years for wrongful death claims.

Note: Surviving spouses, dependent children, and estate representatives can file wrongful death claims on behalf of a patient who died from Actos-related bladder cancer.


Current Status of Actos Litigation#

Actos claims were consolidated into a federal Multidistrict Litigation (MDL No. 2299) in the U.S. District Court for the Western District of Louisiana in 2011 to streamline case processing.

Key Litigation Milestones#

  • 2014: The first bellwether trial resulted in a 9billionpunitivedamagesawardagainstTakeda(9 billion punitive damages award against Takeda (6 billion against Takeda, 3billionagainstEliLilly),whichwaslaterreducedto3 billion against Eli Lilly), which was later reduced to 36.8 million by the presiding judge.
  • 2015: Takeda agreed to a $2.37 billion global settlement to resolve approximately 9,000 pending Actos claims. Over 96% of eligible claimants opted in.
  • 2018: The federal MDL was officially closed in April 2018 after the majority of consolidated cases were resolved through the settlement.

Current Status#

As of 2026, Actos litigation is largely inactive. The federal MDL closed in 2018, and Takeda has resolved the vast majority of claims. Most law firms are no longer accepting new Actos cases. If you believe you have a valid claim, consult a pharmaceutical litigation attorney to discuss whether any legal options remain available in your jurisdiction.


Actos Settlement Details: Payouts, Covered Costs, and Tax Rules#

There is no open global settlement for Actos claims; the 2015 settlement resolved the vast majority of cases. New claims are no longer being accepted by most law firms, as the litigation is largely concluded. If you believe you have a valid claim, consult a pharmaceutical litigation attorney to discuss whether any legal options remain.

Average Payouts#

Payouts from the 2015 global settlement averaged approximately $296,000 per claimant, though amounts varied significantly based on a points-matrix system that evaluated each case individually. Factors affecting payout included:

  • Stage of bladder cancer (stage 3/4 claimants received 2–3x higher payouts than stage 1 claimants)
  • Duration of Actos use
  • Total out-of-pocket medical costs
  • Lost wages and reduced earning capacity
  • Whether the claim is for personal injury or wrongful death

What Settlements Cover#

Approved settlements typically cover:

  1. Past and future medical expenses related to bladder cancer treatment
  2. Lost wages and loss of future earning capacity
  3. Physical pain and emotional suffering
  4. Wrongful death damages (funeral costs, loss of consortium, lost financial support for family members)

Tax Implications#

In the U.S., settlement funds allocated to compensation for physical illness and related medical costs are non-taxable. Portions of a settlement allocated to lost wages or punitive damages are subject to federal and state income tax. We recommend consulting a tax professional to understand your obligations if you receive a settlement.


Next Steps If You Qualify for an Actos Claim#

If you believe you may qualify for an Actos claim, take these steps to explore your options:

  1. Gather supporting documentation: Collect copies of your Actos prescription records, medical records confirming your bladder cancer diagnosis, receipts for medical expenses, and pay stubs if you missed work due to illness.
  2. Consult a pharmaceutical litigation attorney: Most Actos lawyers work on a contingency fee basis, meaning you pay no upfront costs, and they only receive payment (typically 30–40% of your settlement) if you win compensation. Look for a lawyer with experience handling Actos or other pharmaceutical mass tort claims.
  3. File your claim before the statute of limitations expires: Your attorney will confirm the deadline for your state and handle all filing requirements on your behalf.
  4. Await resolution: Most individual Actos claims take 1–3 years to resolve, depending on the complexity of your case. Your attorney will negotiate with the defendant’s legal team and advise you if a settlement offer is fair, or if you should take your case to trial.

Frequently Asked Questions#

Q: Do I need to have taken brand name Actos to qualify for a claim?#

A: No. Eligible claims are now accepted for both brand name Actos and generic pioglitazone, depending on your diagnosis date and the manufacturer of the generic drug you took.

Q: Can I file a claim if I already received a settlement for another diabetes drug lawsuit?#

A: Yes, as long as you have not previously filed or accepted a settlement for an Actos-specific claim.

Q: Will I have to go to court for my Actos claim?#

A: Most Actos claims were settled out of court as part of the 2015 global settlement. You may only be required to appear in court if your case goes to trial, which was rare for eligible, well-documented claims.


References#

  1. diaTribe. (2011). FDA Updates Warnings and Precautions Section of Actos Label after French and German Regulatory Authorities Suspend Drug Due to Possible Increased Risk of Bladder Cancer. Retrieved from https://diatribe.org/diabetes-medications/fda-updates-warnings-and-precautions-section-actos-label-after-french-and
  2. U.S. Judicial Panel on Multidistrict Litigation. (2011). In Re: Actos (Pioglitazone) Products Liability Litigation (MDL No. 2299). Retrieved from https://www.jpml.uscourts.gov/sites/jpml/files/MDL-2299-Remand_Order-05-13.pdf
  3. Takeda Pharmaceuticals. (2015). Takeda Agrees to Settle ACTOS Product Liability Lawsuits and Claims. Retrieved from https://www.takeda.com/en-us/newsroom/news-releases/2015/takeda-agrees-to-settle-actos-product-liability-lawsuits-and-claims-takeda-stresses-continued-commitment-to-actos/
  4. Drugwatch. (2026). Actos Lawsuits — Verdicts, Scandals, Controversies & Settlements. Retrieved from https://www.drugwatch.com/actos/lawsuits/
  5. Miller & Zois. (2024). ACTOS Bladder Cancer Lawsuit — 2024 Look Back. Retrieved from https://www.millerandzois.com/products-liability/drugs/other-drug-cases/actos/

Legalcamp Team

Welcome to Legalcamp, where our team of dedicated professionals brings clarity to the complexities of the law.

Legal Disclaimer

No content on this website should be considered legal advice, as legal guidance must be tailored to the unique circumstances of each case. You should not act on any information provided by Legalcamp without first consulting a professional attorney who is licensed or authorized to practice in your jurisdiction. Legalcamp assumes no responsibility for any individual who relies on the information found on or received through this site and disclaims all liability regarding such information.

Although we strive to keep the information on this site up-to-date, the owners and contributors of this site make no representations, promises, or guarantees about the accuracy, completeness, or adequacy of the information contained on or linked to from this site.